UCB's tau drug flunks phase 2 Alzheimer's trial days after Roche's exit from $120M bet

The week after seeing its partner Roche cut and run, UCB has reported the failure of its anti-tau antibody bepranemab to improve cognition and function in people with early Alzheimer’s disease. But UCB looked past the primary endpoint miss and focused on other results that left it “deeply encouraged” by the trial.